To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer

You may not qualify if:

• Part 2 only, history of prior regimen(s)of platinum-based chemotherapy for metastatic NSCLC and/or history of adjuvant platinum-based chemotherapy with last dose received less than six months prior to the start of current first-line platinum-based chemotherapy for metastatic NSCLC.
• National Cancer Institute Common Terminology for Adverse Events Grade \>3 toxicity
• Prior radiation to \>20% of whole skeleton
• Prior regimen(s) of platinum based chemotherapy for metastatic disease and/or history of adjuvant platinum-based chemotherapy with the last dose received less than six months prior to the start of current first-line platinum-based chemotherapy for metastatic disease
• Central nervous system metastases
• Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic, or genitourinary disease unrelated to underlying malignancy
• Classification of 3 or higher heart failure (as classified by New York Heart Association)
• History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke, if not stable on anticoagulants and/or one of these events occurring in past 6 months
• Diagnosis of a myeloid malignancy or known history of myelodysplasia
• Recent history (within 14 days of Day 1) of IV/oral antibiotics due to post septic episode
• Uncontrolled hypertension. Controlled hypertension is considered clinically stable, and systolic blood pressure (SBP) must be \<150 mmHg and diastolic blood pressure (DBP) must be \< 00 mmHg.
• Known human immunodeficiency virus (HIV)
• Known active hepatitis B or C antibody
• Iron deficiency
• History of anemia as a result of inherited hemoglobinopathy
• +6 more criteria